KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.

Lawrence F Eichenfield, Linda F Stein Gold, Eric L Simpson, Andrea L Zaenglein, April W Armstrong, Megha M Tollefson, Weily Soong, Lara Wine Lee, Alim R Devani, Seth B Forman, Dareen D Siri, Howard Kallender, Brett Angel, Qian Li, Xuejun Chen, Amy S Paller

J Am Acad Dermatol 93(3) 689-698

PMID40378883
PMCID-
DOI10.1016/j.jaad.2025.05.1385
发表日期2025-05-16
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Ruxolitinib (Janus kinase 1 and Janus kinase 2 inhibitor) cream demonstrated efficacy and safety in adolescents and adults with mild-to-moderate atopic dermatitis (AD). OBJECTIVE: To evaluate 8-week efficacy and safety of ruxolitinib cream in children with mild-to-moderate AD. METHODS: This phase 3 study (TRuE-AD3; NCT04921969) enrolled children aged 2-11 years with an Investigator's Global Assessment (IGA) score of 2 or 3 and 3% to 20% affected body surface area. Patients were randomized 2:2:1 to twice-daily ruxolitinib cream (0.75% or 1.5%) or vehicle for 8 weeks. The primary endpoint was the proportion of patients achieving IGA treatment success (IGA-TS; score of 0/1 with ≥2-grade improvement from baseline) at Week 8. RESULTS: Children (N = 330) were randomized to vehicle (n = 65), 0.75% ruxolitinib cream (n = 134), or 1.5% ruxolitinib cream (n = 131). At Week 8, significantly more patients achieved IGA-TS with 0.75%/1.5% ruxolitinib cream (36.6%/56.5%) versus vehicle (10.8%; P = .0001/P < .0001). Improvements in itch and quality of life were also observed. The safety profile was consistent with that observed in adults and adolescents. LIMITATIONS: Enrollment was limited to patients in North America. CONCLUSION: Ruxolitinib cream provided superior improvements versus vehicle in AD signs and symptoms in children with mild-to-moderate AD and was well tolerated.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。